Sign In
30 Mar 2011 16:28
For immediate release | 30 March 2011 |
ABCAM PLC
("Abcam" or "the Company")
Interim Report
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that its Interim Report for the six months ended 31 December 2010 has been posted to shareholders and is available at the Company's investor relations website, www.abcamplc.com.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 71,000 products, most of which are antibodies, from over 250 suppliers and employs 290 staff.
Follow the stocks
